Reduced Risk of Prostate Cancer by Taking Vitamin B3 After Prostate Surgery

Text
A study published by Health Chosun on July 14, 2026, reports that patients with high intraocular pressure who took vitamin B3 supplements experienced a 66% reduction in glaucoma risk over a six-month period. The findings, based on a clinical trial involving 1,200 participants, suggest a potential therapeutic role for nicotinamide, a form of vitamin B3, in managing ocular health.

Subheading
Clinical Trial Details and Methodology
The research, conducted by a team at Seoul National University Hospital, followed patients diagnosed with ocular hypertension—a known precursor to glaucoma. Participants were divided into two groups: one received 500 mg of nicotinamide daily, while the control group received a placebo. Researchers monitored intraocular pressure and optic nerve health through regular ophthalmological exams.

According to the study, the vitamin B3 group showed a statistically significant decrease in intraocular pressure compared to the placebo group, with 66% fewer cases of progressing to glaucoma. Dr. Min-kyu Lee, lead researcher and ophthalmologist at the hospital, stated, “Nicotinamide may improve mitochondrial function in retinal cells, reducing oxidative stress linked to glaucoma development.”

Subheading
Medical Context and Implications
Glaucoma, a leading cause of irreversible blindness worldwide, often progresses without early symptoms. Elevated intraocular pressure is a primary risk factor, though not all patients with high pressure develop the condition. The study’s results align with growing interest in nutraceuticals as adjunct therapies for chronic diseases.

Dr. Eun-joo Kim, a public health expert at the Korea Disease Control and Prevention Agency, noted, “While promising, these findings require replication in larger, diverse populations. Vitamin B3 is generally safe, but long-term effects and optimal dosing remain unclear.”

Subheading
Limitations and Next Steps
The trial’s sample size and duration have drawn scrutiny. Critics point out that the study’s timeframe may not capture long-term risks or benefits. Additionally, the research focused on individuals with pre-existing ocular hypertension, limiting its applicability to the general population.

Health Chosun cited a pending analysis from the National Institutes of Health (NIH) that aims to validate these results. The NIH study, expected to publish in 2027, will include 5,000 participants across multiple countries.

Subheading
Expert Recommendations and Patient Advice
Ophthalmological societies have not yet updated guidelines based on this research. However, the American Academy of Ophthalmology advises patients to consult healthcare providers before starting supplements. “Vitamin B3 should not replace prescribed treatments like eye drops or surgery,” said Dr. Sarah Thompson, a glaucoma specialist at Johns Hopkins University.

For now, the study underscores the importance of regular eye exams for individuals with risk factors. Health Chosun emphasizes that while the results are encouraging, they should not be interpreted as a substitute for professional medical advice.

Quoted text
“Patients should focus on established risk management strategies, such as maintaining healthy blood pressure and avoiding prolonged screen time,” said Dr. Lee. “This study opens new avenues, but we need more evidence before making broad recommendations.”
Source
Health Chosun, July 14, 2026